DrugPatentWatch Database Preview

Pfizer Company Profile

PFIZER has one hundred and fifty-five approved drugs.

There are forty US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are eight hundred and forty-one patent family members on PFIZER drugs in sixty-seven countries and one hundred and seventy-five supplementary protection certificates in nineteen countries.

International Patents:	841
US Patents:	40
Tradenames:	122
Ingredients:	105
NDAs:	155
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	10,723,730	Start Trial	Y	Y		Start Trial
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	6,936,612	Start Trial	Y	Y		Start Trial
Pfizer	PFIZERPEN-A	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	062050-002	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999	5,545,413	Start Trial
Pfizer	MINIPRESS	prazosin hydrochloride	CAPSULE;ORAL	017442-002	Approved Prior to Jan 1, 1982	3,511,836	Start Trial
Pfizer	ZYVOX	linezolid	SOLUTION;INTRAVENOUS	021131-001	Apr 18, 2000	5,688,792*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Oral Solution	20 mg/mL	➤ Subscribe	2010-05-19
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2005-12-21
➤ Subscribe	Injection	2 mg/mL, 300 mL bag	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	➤ Subscribe	2008-12-30
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Oral Suspension	100 mg/5 mL	➤ Subscribe	2009-08-03
➤ Subscribe	Injection	2 mg/mL, 100 mL bag	➤ Subscribe	2009-12-29
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1230209	PA2007008,C1230209	Lithuania	Start Trial	PRODUCT NAME: FESOTERODINUM; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010 20070420
0253738	C960002	Netherlands	Start Trial	PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
1746976	2017C/027	Belgium	Start Trial	PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.